Fatigue is one of the most common and disabling side effects of cancer and its treatment. Although research typically has focused on fatigue that occurs during and after treatment, patients may experience fatigue even before treatment onset. The current study was designed to identify biobehavioral risk factors associated with fatigue before adjuvant therapy in women with early-stage breast cancer. METHODS: Patients with stage 0 to stage IIIA breast cancer (270 women) were recruited before the onset of adjuvant or neoadjuvant therapy with radiotherapy, chemotherapy, and/or endocrine therapy. Host factors that may influence fatigue were identified from an empirically based, biobehavioral model and assessed using self-report questionnaires, medical record review, and blood collection (for genetic data). Fatigue was assessed by questionnaire. Linear regression analyses were used to evaluate the association between host factors and dimensions of fatigue, with general fatigue as the primary dimension of interest. RESULTS: Fatigue was elevated at the pretreatment assessment compared with published controls. Bivariate analyses identified demographic, cancer-related, and biobehavioral correlates of fatigue. In the multivariable model, predictors of general fatigue included younger age, lower educational level, lower cancer stage, and history of childhood maltreatment (all P values <.05), with the full model accounting for approximately 18.4% of the variance in fatigue. Secondary analyses identified common and specific predictors of emotional, mental, and physical dimensions of fatigue. CONCLUSIONS: Among women who have not yet initiated treatment of breast cancer, demographic and psychosocial factors are associated with elevated fatigue and could be used to identify at-risk patients for early intervention. Cancer 2019;125:633-641.
INTRODUCTION
Fatigue is one of the most common and debilitating side effects of cancer and its treatment. 1, 2 Cancer-related fatigue has adverse emotional, social, occupational, and economic consequences for patients and their caregivers, 3 and may impact treatment adherence and survival. 4 Most studies in this area have focused on fatigue that occurs during and after treatment. 5 However, some patients experience significant fatigue even before treatment onset, 6 which may portend a more difficult treatment course and slower recovery. Indeed, evidence suggests that pretreatment fatigue is one of the strongest predictors of persistent fatigue up to 5 years after treatment completion. [7] [8] [9] [10] [11] [12] [13] [14] To our knowledge, to date, there has been minimal examination of factors associated with fatigue at this critical stage of the cancer trajectory. Identifying host factors that contribute to fatigue before adjuvant treatment will help to identify vulnerable patients who would benefit from early, targeted intervention and elucidate underlying mechanisms.
Cancer-related fatigue is multifactorial and can be influenced by a variety of demographic, medical, psychosocial, behavioral, and biological factors. 2 An empirically based biobehavioral model of cancer-related fatigue that identifies key factors associated with fatigue during and after treatment has been proposed. 1 However, it is not known whether this model is relevant for patients before adjuvant therapy. Research regarding other behavioral symptoms (eg, insomnia) demonstrates that factors involved with symptom initiation may differ from those involved in symptom persistence. 15 Similarly, there may be unique predictors of fatigue experienced early in the cancer trajectory, before the initiation of adjuvant
Cancer February 15, 2019 therapy. The few studies to examine correlates of fatigue before treatment onset have identified demographic and medical factors associated with fatigue, including younger age, children living in the home, and higher body mass index (BMI). 16 Fatigue also is correlated with other symptoms before treatment onset, including depressed mood and sleep disturbance, [16] [17] [18] although it is unclear whether these are a cause or consequence of fatigue. Other host factors that have emerged as predictors of fatigue during and after treatment have rarely have been evaluated before treatment onset, including history of depression, [19] [20] [21] [22] childhood trauma, [23] [24] [25] [26] and genetic risk factors, particularly variants in genes involved in inflammation and immune response (eg, interleukin 1 [IL 1], tumor necrosis factor A [TNFA], and IL 6). 27 Importantly, these host factors are present before the diagnosis of cancer, which clarifies the temporal nature of their association with fatigue.
The multidimensional nature of cancer-related fatigue further complicates the identification of risk factors and the development of effective interventions. The defining characteristic of cancer-related fatigue is a subjective feeling of tiredness, 28 but it also may include a sense of physical, emotional, and/or cognitive tiredness or exhaustion. 29, 30 However, many studies use unidimensional measures of fatigue that focus primarily on fatigue severity or collapse across dimensions for analyses. This limitation is striking given evidence that different dimensions of fatigue have distinct correlates and demonstrate different responses to cancer treatment and to interventions. [31] [32] [33] The goal of the current study was to identify correlates of fatigue among women diagnosed with early-stage breast cancer who had not yet initiated adjuvant therapy. Drawing from a biobehavioral model of fatigue, 1 we tested key demographic, medical, psychosocial, and biological factors that have been linked with fatigue across the cancer continuum. Among the psychosocial and biological risk factors, we focused on stable host factors rather than more transient factors that could be a consequence of fatigue. We were particularly interested in history of depression, childhood adversity, and cytokine genetic polymorphisms, which have been linked with fatigue during and after cancer treatment, [19] [20] [21] [22] [23] [24] [25] [26] [27] 34 Our primary analyses focused on general fatigue, which includes feelings of tiredness and is most comparable to unidimensional measures of fatigue used in previous research. Secondary analyses examined whether these risk factors also were associated with other dimensions of fatigue, including physical, mental, and emotional fatigue.
MATERIALS AND METHODS

Patients and Procedures
Patients were recruited from oncology practices in Los Angeles to participate in a longitudinal, observational study of cancer-related fatigue (RISE study). Women were eligible if they had been recently diagnosed with stage 0 to stage IIIA breast cancer and had not yet initiated adjuvant or neoadjuvant therapy with radiotherapy, chemotherapy, or endocrine therapy. Primary recruitment sites were the University of California at Los Angeles and Cedars-Sinai Medical Center.
Participants completed assessments at baseline; at the end of treatment (for those who received radiotherapy and/or chemotherapy); and at 6-month, 12-month, and 18-month posttreatment follow-ups. In the current study, we focused on the baseline assessment. The institutional review boards at the University of California at Los Angeles and Cedars-Sinai Medical Center approved the study, and all participants provided written informed consent.
Measures
Data were collected through self-report questionnaires, interviews, blood collection, and medical chart review.
Fatigue was assessed with the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), which includes 4 subscales assessing distinct dimensions of fatigue. 29, 35 General fatigue assesses the degree to which respondents felt tired, worn out, sluggish, and fatigued within the past week, and was the primary outcome of interest. Physical fatigue assesses feelings of weakness, heaviness, and achiness within the past week; mental fatigue assesses trouble remembering things and paying attention, difficulty concentrating, and confusion within the past week; and emotional fatigue assesses feeling upset, nervous, sad, depressed, and tense within the past week. Across subscales, higher scores indicate more fatigue. Demographic characteristics were obtained from self-report at baseline and included age, race/ethnicity, marital status, income, educational level, employment status, and presence of children in the home.
Disease and treatment-related information was obtained from medical record abstraction and included cancer stage, type of surgery received, and time from diagnosis to baseline assessment. Cancer stage was determined using the 7th edition of the American Joint Committee on Cancer staging manual.
Precancer medical comorbidities were assessed with a questionnaire version of the Charlson Comorbidity Index, which is a reliable and valid measure that includes Cancer February 15, 2019 a variety of chronic diseases including heart attack, stroke, cardiovascular disease, asthma, diabetes, autoimmune disease, and dementia. 36 Height and weight were measured at baseline for the determination of BMI.
A history of childhood maltreatment was assessed with the Childhood Trauma Questionnaire, 37 a 28-item measure that includes questions regarding physical, emotional, and sexual abuse, as well as physical and emotional neglect that occurred during childhood. Women were categorized into 1 of 3 maltreatment groups using a scoring algorithm with established sensitivity and specificity: 1) no maltreatment; 2) physical and/or emotional abuse or neglect but no sexual abuse; and 3) sexual abuse with or without physical and/or emotional abuse or neglect. 38 History of major depressive disorder prior to the cancer diagnosis was determined using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) Axis I Disorders (SCID). The SCID was administered by trained interviewers and interviews were reviewed and scored by a consensus panel led by a psychiatrist with expertise in depression (M.I.).
Genomic DNA was extracted from peripheral blood leukocytes and assayed using a commercial TaqMan Genotyping Assay (Applied Biosystems, Foster City, California) performed on a iCycler real-time polymerase chain reaction instrument (BioRad, Hercules, California) following the manufacturer's protocols, as previously described. 39 We focused on single-nucleotide polymorphisms (SNPs) in genes encoding proinflammatory cytokines that have been linked to cancer-related fatigue, including IL 1B-511 C>T (rs16944), IL 6-174 G>C (rs1800795), and TNF 308 G>A (rs1800629).
39-41
Data and Power Analysis
Bivariate linear regression analyses assessed the relationship between each predictor and each dimension of fatigue, with general fatigue as the primary outcome. Given our interest in identifying predictors of different dimensions of fatigue (rather than characterizing fatigue groups or cases), fatigue was treated as a continuous variable in all analyses. Variables that were associated with an MFSI-SF subscale with bivariate P < .10 were included in a multivariable model for that subscale. Multivariable linear regression models were fit using multiple imputation (20 imputations were generated using chained equations) 42 to handle missing values, and coefficient estimates and standard errors were obtained using the rules of Rubin. Multivariable models controlled for time since diagnosis. The percentage of variance explained, as measured by R Analyses were conducted using Stata statistical software (version 13.1; StataCorp LLC, College Station, Texas). The target sample size was based on the prevalence of key predictor variables and the magnitude of the hypothesized association with fatigue. Power analyses determined that 240 to 280 patients would be required to detect effect sizes of 0.35 to 0.45.
RESULTS
Enrollment began in January 2013 and ended in July 2015. Over this period, a total of 409 women were screened, 302 of whom met initial eligibility criteria and consented for participation. Thirty-two women later were determined to be ineligible (5 women) or failed to complete the baseline questionnaire (27 women). Thus, the final sample consisted of 270 women.
Characteristics of the study participants are shown in Table 1 . Women were aged 56 years on average and primarily were white, college educated, and working full time or part time. The majority had been diagnosed with stage I (47%) or stage II (24%) breast cancer and were treated with lumpectomy or mastectomy prior to study enrollment. Note that 10% of study participants had not undergone surgery prior to enrollment because they were scheduled to undergo neoadjuvant chemotherapy before surgery. The median number of days from diagnosis to study enrollment/baseline assessment was 56; approximately 80% of patients were enrolled within 3 months of diagnosis, although a few (6 patients) were enrolled >6 months after diagnosis, typically because they waited several months before initiating adjuvant treatment. Approximately 23% of patients had a history of major depressive disorder prior to their breast cancer diagnosis, which is higher than that reported in patients with breast cancer with similar clinical characteristics (17%) 21 but lower than that reported in a community sample of midlife women (32%). 44 Approximately 40% of patients reported a history of emotional, physical, or sexual maltreatment as children, which is comparable to demographically similar samples of women. 38 The average score on the MFSI-SF general fatigue subscale was 7.8 and ranged from 0 to 24. In the validation study for this scale, 29 the average score among women with no history of cancer was 5.06, indicating that fatigue was elevated in the current study sample even before adjuvant therapy had begun. Mean scores on each of the MFSI-SF subscales, and correlations among subscales, are reported in Table 2 .
Cancer February 15, 2019 Bivariate Correlates of Fatigue Bivariate analyses identified several significant correlates of fatigue (Table 3) . Primary analyses focusing on general fatigue demonstrated that women of younger age, of lower income and/or educational level, with earlier stage disease, who were treated with mastectomy, and who had a history of childhood maltreatment or a history of depression reported higher levels of general fatigue (all P values <.05). Income and childhood maltreatment also were found to be associated with significantly higher levels of emotional, physical, and mental fatigue (P values <.05); individual correlates of different fatigue dimensions are reported in Table 3 .
Multivariable Models of Fatigue
We next fit multivariable linear regression models including variables that were associated at P <.10 in bivariate analyses. Results are shown in Table 4 . For general fatigue, younger age, lower educational level, lower disease stage, and a history of childhood maltreatment were found to be significant predictors (all P values <.05). These factors also were found to be associated with other dimensions of fatigue, although childhood maltreatment was the only factor associated with all fatigue dimensions at P ≤.05. The association between childhood maltreatment and general fatigue is shown in Figure 1 . Other risk factors were associated with specific dimensions of fatigue in the multivariable models. In particular, the presence of medical comorbidities was a significant predictor of physical and mental fatigue, and a history of depression was a significant predictor of emotional and mental fatigue. Among the genetic risk factors assessed, only one demonstrated a significant association with fatigue: high-expression variants of the IL 6 SNP were found to be associated with significantly higher levels of physical fatigue. Together, the predictors explained approximately 18% to 22% of the variance in general, physical, and mental fatigue, but only 13.9% of the variance in emotional fatigue.
DISCUSSION
The current study applied a biobehavioral model of cancer-related fatigue to identify risk factors for fatigue before the commencement of adjuvant therapy in a large sample of women with breast cancer. This point in the cancer trajectory has received minimal empirical attention to date, despite evidence that pretreatment fatigue is one of the strongest and most consistent predictors of posttreatment fatigue and may set the stage for elevated fatigue years after treatment. 7, 8 Across general and specific subdimensions of fatigue, women of younger age, those of lower income or educational level, and those who had a history of childhood maltreatment reported elevated symptoms, suggesting a vulnerable phenotype. Also notable were those factors that were consistently not Cancer February 15, 2019 found to be associated with fatigue, including partner status, race/ethnicity, and BMI. Psychosocial factors emerged as key predictors of fatigue in the current study sample. Women who had experienced abuse or neglect as children (40% of the sample) reported higher levels of all dimensions of fatigue, and those with a history of depression (23%) reported significantly higher levels of emotional and mental fatigue in bivariate analyses. These factors are known to increase the risk of physical and behavioral symptoms in other contexts, 45, 46 but have only recently been examined in relation to cancer-related fatigue. [19] [20] [21] [22] [24] [25] [26] There are several mechanisms through which these factors may influence fatigue, including alterations in neural, neuroendocrine, immune, and/or behavioral processes. [47] [48] [49] [50] In particular, both childhood adversity and depression are associated with elevated inflammation, [50] [51] [52] which has been linked with cancer-related fatigue, 1, 53 suggesting that inflammation may contribute to fatigue even before adjuvant treatment in vulnerable patients. Indeed, one small study Cancer February 15, 2019 found that childhood trauma was associated with elevated fatigue and inflammation before radiotherapy in women with breast cancer. 26 It is interesting to note that childhood adversity and a history of depression demonstrated differential associations with specific dimensions of fatigue in multivariable models. Results from these analyses suggest that a history of depression and childhood adversity make unique independent contributions to mental fatigue, but that childhood adversity is more strongly associate with general fatigue and a history of depression is more strongly associated with emotional fatigue in this sample. These findings highlight the importance of examining dimensions of fatigue and provide insight into their distinct associations with psychosocial vulnerability factors.
The results of the current study also demonstrated the importance of socioeconomic status in the experience of fatigue. Women with lower levels of income or education may be less prepared for the demands of diagnosis, surgery, and adjuvant treatment preparation, or may have fewer financial resources with which to meet those demands. Furthermore, the current study results highlighted age as a significant risk factor for general, emotional, and mental fatigue, with younger women at higher risk. These findings are consistent with previous research, 19, 54, 55 and underscore the vulnerability of younger women to the behavioral side effects of breast cancer. 56 Although certain risk factors were found to be associated with multiple dimensions of fatigue, results also revealed more specific effects. This was particularly evident for physical fatigue, which had several unique predictors in multivariable models, including receipt of mastectomy and high-expression variants of the IL 6-174 SNP. These findings suggest that medical and genetic risk factors may play a stronger role in physical fatigue, operationalized by the MFSI-SF as feelings of bodily weakness, achiness, and heaviness. Of note, previous studies have demonstrated associations with variants in the IL 6 gene and fatigue before, during, and after cancer treatment. 39, 57, 58 In addition to mastectomy, the one disease-related variable found to predict fatigue in multivariable models was cancer stage; women with lower stage disease reported higher levels of general, mental, and physical fatigue. In the posttreatment period, cancer stage typically is not strongly associated with fatigue, depression, and other aspects of quality of life. 59 However, it is possible that stage of disease may be more salient closer to the time of diagnosis, when women are learning about the treatment and survival-related implications of their cancer. Nevertheless, the finding that women with lower stage disease reported more fatigue is unexpected, Cancer February 15, 2019 because previous studies typically have found that lower cancer stage is associated with lower (rather than higher) fatigue, if any association is reported. 60 This unexpected finding requires examination in future research.
Factors that were not found to be associated with fatigue in the current study sample also merit discussion. In particular, we found no association between partner status and fatigue, although previous work has suggested that partnered women report lower levels of fatigue, at least in the posttreatment period. 54, 60 It is possible that that the instrumental support provided by a partner may become more important during and after treatment as symptoms increase. Furthermore, BMI was not found to be associated with fatigue, although previous studies have shown that BMI is associated with fatigue before 16 and after treatment 61 in women with breast cancer. There also was no association noted between race/ethnicity and fatigue in this sample, other than elevated physical fatigue among Hispanic women. These findings are consistent with our previous research with survivors of breast cancer, 54 and with results from several large samples of mixed cancer survivors, 22 ,62 although racial differences in fatigue have been observed during cancer treatment. 22 Several limitations of the current study should be noted. Although the study was designed to evaluate fatigue relatively early in the cancer trajectory, in the majority of cases participants were assessed after surgical resection of the primary tumor (ie, unless they were scheduled to receive neoadjuvant chemotherapy). Surgery can influence fatigue 63 ; indeed, we found that treatment with mastectomy was associated with higher levels of physical fatigue. It would be ideal to obtain a presurgical measure of fatigue to better capture a true pretreatment baseline, although there are challenges with recruitment and assessment during the interval between diagnosis and surgery. In addition, our ability to identify socioeconomic correlates of fatigue may have been limited by characteristics of the study sample, which was predominantly white and well-educated, although we did find evidence of elevated fatigue among those of lower income and/or educational level as well as higher levels of physical fatigue among Hispanic women. Furthermore, the majority of women had early-stage (stage I or stage II) breast cancer, which limits the generalizability of the results.
There is growing evidence of substantial individual variability in the experience of fatigue during and after treatment, which may be present even before the onset of treatment. Indeed, a recent study of women with early-stage breast cancer assessed before surgery and at 4 month and 8 month follow-ups identified 2 groups of patients with distinct fatigue trajectories: one with low fatigue before surgery that remained low and stable throughout the assessment period and one with high fatigue before surgery that increased during treatment and then declined by 8 months (although never to presurgery levels). 64 This suggests that much of the variance in cancer-related fatigue may be driven by factors that predate the cancer experience. The current study identified several of these factors, although it should be noted that the combination of medical, demographic, disease, and psychosocial risk factors included herein explained approximately 20% of the variance in pretreatment fatigue. It will be important to determine whether these factors also are associated with increased fatigue in the immediate aftermath of adjuvant treatment and in the subsequent months and years, or if different processes play a more important role at later stages of survivorship. The findings of the current study also offer insight into different dimensions of fatigue and demonstrate common and unique predictors of these dimensions. From a clinical perspective, several of these risk factors may not be "on the radar" of treating physicians, including childhood maltreatment, but may aid in the identification of vulnerable patients and the delivery of early interventions to those most in need. 
